

Current report № 121 /2024

Dated November 29, 2024

NOTIFICATION

“Sopharma” AD (the Company) notifies, that with the completion of the respective due diligence procedures the first stage of the transaction for acquisition of a pharmaceutical product portfolio consisting of CHC and prescription products. The amount of EUR 40 million due at this stage is financed with own funds and through an investment loan from a financial institution which has already been secured.

The transfer of marketing authorizations and trademarks and the organization of the trading activities on the respective market will follow.

Ognian Donev